SG/PUT/ELI LILLY & CO/550/0.01/20.09.24 | Delayed Deutsche Boerse AG 03:48:07 2024-07-16 pm EDT | ||
| 0.001 EUR | 0.00% |
|
| 3 months | -98.53% | ||
| 6 months | -99.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.001 | 0.00% |
| 24-07-15 | 0.001 | 0.00% |
| 24-07-12 | 0.001 | 0.00% |
| 24-07-11 | 0.001 | 0.00% |
| 24-07-10 | 0.001 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update July 16, 2024 at 03:48 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SW3ZJX |
| ISIN | DE000SW3ZJX5 |
| Date issued | 2023-09-26 |
| Strike | 550 $ |
| Maturity | 2024-09-20 (66 Days) |
| Parity | 100 : 1 |
| Emission price | 0.51 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.67 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.019 € |
| Spread % | 95.00% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
941.6
USD
Average target price
893.8
USD
Spread / Average Target
-5.08%
- Stock Market
- Warrants
- Warrant
